中文摘要：

肿瘤多药耐药性（multipledrugresistance，MDR）的发生往往伴随着多药耐药基因如MDRl、MRP1和BCRP等高表达，其中MDRl基因编码的P一糖蛋白（P-glycoprotein，P-gp）是目前公认可以诱发癌细胞发生MDR的重要分子。传统研究认为P-gp主要是作为一个药物泵将化疗药物从细胞内排出从而导致MDR。然而系列研究发现，除了介导MDR以外，P-gp还能够调节癌细胞的生长、增殖、凋亡、迁移和侵袭等其他生物学行为；而且研究表明P—gp的这些作用可以依赖，也可以不依赖于其药物泵的功能。这些结果表明P—gp能够通过一些新的机制促进肿瘤的进展。本文主要针对P—gP在促进肿瘤进展中的作用进行综述。

英文摘要：

The acquisition of multiple drug resistance （MDR） phenotype is associated with the overexpression of multidrug resis- tance-associated genes, such as MDR1, MRP1, and BCRP. P-glycoprotein （P-gp）, encoded by MDR1, is one of the most extensivelycharacterized MDR transporters in cancer. P-gp mainly functions as a drug pump that excretes chemotherapeutic drugs from cancer cells. However, P-gp participates in cancer progression-related processes, such as cancer cell proliferation, growth, apoptosis, migra- tion, and invasion. Several functions are independent of drug transporter activities. These data suggest that novel mechanisms are em- ployed by P-gp to promote cancer progression. Thus, novel functions of P-gp should be understood and mechanisms by which P-gp pro- motes cancer aggravation should be determined to improve cancer diagnosis and treatment. In this review, recent research progress on novel contributions of P-gp to cancer progression is summarized.